The Joint (JYNT) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of The Joint (NASDAQ:JYNT) from a hold rating to a buy rating in a report released on Saturday morning. Zacks Investment Research currently has $7.75 target price on the stock.

According to Zacks, “The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company’s plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. “

How to Become a New Pot Stock Millionaire

Several other analysts have also recently weighed in on the stock. Lake Street Capital initiated coverage on shares of The Joint in a research report on Wednesday, March 28th. They set a buy rating on the stock. Maxim Group restated a buy rating and set a $7.00 price objective on shares of The Joint in a research report on Friday, March 9th. Finally, ValuEngine upgraded shares of The Joint from a sell rating to a hold rating in a research report on Sunday, December 31st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $7.05.

The Joint stock opened at $7.04 on Friday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.20. The Joint has a fifty-two week low of $3.41 and a fifty-two week high of $7.25.

The Joint (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, March 8th. The company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $6.93 million for the quarter, compared to analysts’ expectations of $6.48 million. The Joint had a negative net margin of 13.01% and a negative return on equity of 66.74%. equities analysts expect that The Joint will post 0.08 earnings per share for the current year.

Large investors have recently modified their holdings of the stock. Deutsche Bank AG raised its position in The Joint by 3,839.1% in the 4th quarter. Deutsche Bank AG now owns 59,087 shares of the company’s stock worth $293,000 after purchasing an additional 57,587 shares during the period. Renaissance Technologies LLC purchased a new position in The Joint in the 4th quarter worth $379,000. Russell Investments Group Ltd. raised its position in The Joint by 28.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 112,900 shares of the company’s stock worth $538,000 after purchasing an additional 25,000 shares during the period. Finally, Skylands Capital LLC raised its position in The Joint by 11.0% in the 4th quarter. Skylands Capital LLC now owns 612,529 shares of the company’s stock worth $3,038,000 after purchasing an additional 60,900 shares during the period. Institutional investors own 49.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.chaffeybreeze.com/2018/04/17/the-joint-jynt-raised-to-buy-at-zacks-investment-research.html.

The Joint Company Profile

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2017, the company operated 352 franchised clinics and 47 company-owned or managed clinics.

Get a free copy of the Zacks research report on The Joint (JYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for The Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Joint and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply